Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 May;64(5):489-95.
doi: 10.1007/s00228-007-0443-9. Epub 2008 Jan 8.

Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients

Affiliations
Clinical Trial

Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients

Anna Ferrari et al. Eur J Clin Pharmacol. 2008 May.

Abstract

Background: The marketing of sumatriptan, a selective serotonin (5-HT) 1B/1D agonist, first of the class of triptans, has increased the therapeutic options for the treatment of migraine attacks. However, almost one third of patients in clinical trials fail to have headache relief after oral administration of sumatriptan.

Objective: To evaluate whether the interindividual differences in the clinical response following oral administration of sumatriptan are due to differences in its pharmacokinetics.

Methods: We compared the pharmacokinetics of sumatriptan after oral (100 mg) and subcutaneous (6 mg) administration in two age- and gender-matched groups: ten subjects (group A) with satisfactory response and ten (group B) with unsatisfactory response to oral sumatriptan. Patients were studied during headache-free intervals. Blood samples were taken serially from baseline to 360 min after oral administration and from baseline to 180 min after subcutaneous injection. Sumatriptan plasma concentrations were determined by high-performance liquid chromatography (HPLC) with an electrochemical detector.

Results: Following oral dosing, patients of group A absorbed sumatriptan significantly faster and achieved early plasma levels significantly higher than patients of group B. The systemic exposure to sumatriptan during the first 2 h, which are the most important for rapid onset of action and for antimigraine efficacy, was significantly greater in group A than in group B (P < 0.001, Student's t test for independent data). On the other hand, after subcutaneous injection of sumatriptan, the profile of the curves was similar in all patients, and there were no differences in pharmacokinetics between group A and group B.

Conclusion: The slow rate and low extent of absorption of the drug during the first 2 h after dosing observed in patients of group B could explain their unsatisfactory response to oral sumatriptan.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Headache. 2005 Jun;45(6):632-7 - PubMed
    1. Clin Ther. 2000 Sep;22(9):1035-48 - PubMed
    1. Headache. 2007 Feb;47(2):247-52 - PubMed
    1. J Pharm Sci. 1994 Feb;83(2):212-5 - PubMed
    1. Clin Ther. 2004 Feb;26(2):214-23 - PubMed

Publication types

LinkOut - more resources